(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 7.02% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Cytek Biosciences's revenue in 2026 is $201,493,000.On average, 7 Wall Street analysts forecast CTKB's revenue for 2026 to be $27,201,208,778, with the lowest CTKB revenue forecast at $25,825,722,322, and the highest CTKB revenue forecast at $28,237,322,874. On average, 6 Wall Street analysts forecast CTKB's revenue for 2027 to be $29,346,710,547, with the lowest CTKB revenue forecast at $27,048,234,116, and the highest CTKB revenue forecast at $30,858,460,147.
In 2028, CTKB is forecast to generate $31,830,299,175 in revenue, with the lowest revenue forecast at $29,605,096,321 and the highest revenue forecast at $33,812,542,272.